Cargando…
Belantamab Mafodotin (GSK2857916) Drives Immunogenic Cell Death and Immune-mediated Antitumor Responses In Vivo
B-cell maturation antigen (BCMA) is an attractive therapeutic target highly expressed on differentiated plasma cells in multiple myeloma and other B-cell malignancies. GSK2857916 (belantamab mafodotin, BLENREP) is a BCMA-targeting antibody–drug conjugate approved for the treatment of relapsed/refrac...
Autores principales: | Montes de Oca, Rocio, Alavi, Alireza S., Vitali, Nick, Bhattacharya, Sabyasachi, Blackwell, Christina, Patel, Krupa, Seestaller-Wehr, Laura, Kaczynski, Heather, Shi, Hong, Dobrzynski, Eric, Obert, Leslie, Tsvetkov, Lyuben, Cooper, David C., Jackson, Heather, Bojczuk, Paul, Forveille, Sabrina, Kepp, Oliver, Sauvat, Allan, Kroemer, Guido, Creighton-Gutteridge, Mark, Yang, Jingsong, Hopson, Chris, Yanamandra, Niranjan, Shelton, Christopher, Mayes, Patrick, Opalinska, Joanna, Barnette, Mary, Srinivasan, Roopa, Smothers, James, Hoos, Axel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9398105/ https://www.ncbi.nlm.nih.gov/pubmed/34253590 http://dx.doi.org/10.1158/1535-7163.MCT-21-0035 |
Ejemplares similares
-
MM-250: Impact of Prolonged Dose Delays on Response with Belantamab Mafodotin (Belamaf; GSK2857916) Treatment in the DREAMM-2 Study: 13-Month Follow-Up
por: Cohen, Adam D, et al.
Publicado: (2020) -
Functional Genomic Identification of Predictors of Sensitivity and Mechanisms of Resistance to Multivalent Second-Generation TRAIL-R2 Agonists
por: Grinkevitch, Vera, et al.
Publicado: (2022) -
Antibody–Drug Conjugate Efficacy in Neuroblastoma: Role of Payload, Resistance Mechanisms, Target Density, and Antibody Internalization
por: Buongervino, Samantha, et al.
Publicado: (2021) -
A FZD7-specific Antibody–Drug Conjugate Induces Ovarian Tumor Regression in Preclinical Models
por: Do, Myan, et al.
Publicado: (2022) -
First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody–Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer
por: Pegram, Mark D., et al.
Publicado: (2021)